173 completed, 120 active not recruiting, 97 terminated, 62 recruiting. 517 Phase 2, 134 Phase 1, 15 Phase 3.
Follow Opdivo: new trials by email Literature Review of Opdivo trials Research Report on Opdivo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC Nivolumab - Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor | Phase 2 | Not yet recruiting | National Taiwan University Hospital | 40 | 2026-11-02 | 2026-10-28 |
| Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases Bevacizumab, Ipilimumab, Nivolumab - Melanoma Brain Metastases | Phase 1 / Phase 2 | Recruiting | Melanoma and Skin Cancer Trials Limited | 46 | 2026-08-31 | 2026-10-13 |
| Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL Nivolumab, Doxorubicin Hydrochloride, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 15 | 2026-08-19 | 2026-08-31 |
| First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept - Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 26 | 2026-07-07 | 2026-07-10 |
| A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) Fianlimab, Ipilimumab, Nivolumab - Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC) | Phase 2 | Recruiting | Brian Rini | 120 | 2026-04-29 | 2026-09-04 |
| VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 18 | 2026-04-21 | 2026-06-05 |
| BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 43 | 2025-12-12 | 2026-10-02 |
| ONO-4538 Study in Patients With Richter's Transformation ONO-4538 - Richter's Transformation | Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 14 | 2025-11-19 | 2026-02-13 |
| Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis Zanzalintinib, Nivolumab - Locally Advanced Renal Cell Carcinoma | Phase 2 | Recruiting | Qian Qin | 69 | 2025-10-30 | 2026-09-04 |
| Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Acral Melanoma, Advanced Cutaneous Melanoma | Phase 2 | Recruiting | Emory University | 99 | 2025-10-29 | 2025-11-12 |
| NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer Oxaliplatin, Irinotecan, Folinic Acid - Pancreatic Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 20 | 2025-09-04 | 2026-05-05 |
| Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma Nivolumab, Relatlimab plus Nivolumab - Basal Cell Carcinoma | Phase 2 | Recruiting | University of California, San Diego | 30 | 2025-08-21 | 2026-07-28 |
| Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 55 | 2025-08-15 | 2026-07-31 |
| PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma Nivolumab, N-EACOPD-14, N-AVD - Hodgkin Lymphoma, Hodgkin Disease | Phase 2 | Recruiting | National Research Center for Hematology, Russia | 30 | 2025-07-29 | 2025-10-06 |
| Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy Atezolizumab, Biospecimen Collection, Cemiplimab - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Emory University | 20 | 2025-04-09 | 2026-02-12 |
| Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma Biospecimen Collection, Computed Tomography, Dacarbazine - Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma | Phase 2 | Recruiting | University of Washington | 125 | 2025-03-06 | 2026-09-09 |
| Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel Nivolumab - Multiple Myeloma | Phase 2 | Active not recruiting | Wake Forest University Health Sciences | 1 | 2025-02-28 | 2026-07-13 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors BMS-986507, Osimertinib, Pembrolizumab - Lung Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 416 | 2025-02-04 | 2026-09-23 |
Showing 20 of 517. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (65) · Melanoma (65) · Carcinoma, Renal Cell (44) · Lung Neoplasms (30) · Neoplasm Metastasis (28) · Colorectal Neoplasms (27) · Carcinoma, Hepatocellular (25) · Squamous Cell Carcinoma of Head and Neck (23) · Neoplasms (21) · Hodgkin Disease (20) · Carcinoma, Transitional Cell (17) · Stomach Neoplasms (16) · Urinary Bladder Neoplasms (15) · Pancreatic Neoplasms (14) · Prostatic Neoplasms (14)
National Cancer Institute (NCI) (57) · Bristol-Myers Squibb (51) · M.D. Anderson Cancer Center (45) · Dana-Farber Cancer Institute (16) · Emory University (10) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (10) · H. Lee Moffitt Cancer Center and Research Institute (8) · Massachusetts General Hospital (7) · Washington University School of Medicine (7) · Northwestern University (6) · St. Petersburg State Pavlov Medical University (6) · University of Washington (6) · City of Hope Medical Center (5) · National Cancer Centre, Singapore (5) · Sarcoma Oncology Research Center, LLC (5)
United States (397) · Australia (55) · Canada (54) · Spain (54) · France (41) · Italy (38) · Germany (36) · United Kingdom (30) · Netherlands (25) · Belgium (22) · Poland (19) · Singapore (16) · Chile (15) · Argentina (14) · Russia (14)
Alex F Herrera (3) · Eric Jonasch, MD (3) · Mariano Provencio, MD (3) · Sant P Chawla, MD (3) · Sunyoung Lee (3) · Baruch Brenner, Prof (2) · Boris V Afanasyev, Ph.D (2) · Brigette B Ma (2) · Douglas R Adkins, M.D. (2) · Erlinda M Gordon, MD (2) · Howard Safran, MD (2) · Jonathan Cebon, MD (2)
PMID 31401903, PMID 32852531, PMID 33394722, PMID 36648215, PMID 39462179, PMID 39777725, PMID 12377653, PMID 20530316, PMID 21239400, PMID 22590666, PMID 24089446, PMID 25482239, PMID 25631445, PMID 25650315, PMID 26586415, PMID 26773716, PMID 27234989, PMID 27269947, PMID 27718784, PMID 28223062, PMID 28295222, PMID 28734759, PMID 28916527, PMID 29355075, PMID 29370992, PMID 29584545, PMID 29602646, PMID 29628312, PMID 29692997, PMID 29982279, PMID 29983880, PMID 30001986, PMID 30097571, PMID 30134131, PMID 30249211, PMID 30267032, PMID 30309915, PMID 30367283, PMID 30509740, PMID 30647454, PMID 30654297, PMID 30785829, PMID 31105267, PMID 31276163, PMID 31399043, PMID 31400961, PMID 31422205, PMID 31467059, PMID 31538815, PMID 31679945
2016 (16), 2018 (14), U10CA180820 (11), U10CA180821 (11), 2017 (10), P30CA138292 (7), U10CA180868 (7), U10CA180888 (7), P30CA060553 (6), 2023 (4), P30CA015083 (4), U24CA196172 (4), UM1CA186686 (4), UM1CA186691 (4), UM1CA186704 (4)